Sanofi India Limited has announced a crucial Board of Directors meeting scheduled for Wednesday, February 25, 2026. The primary agenda items include the consideration and approval of the Audited Financial Results and Statements for the Quarter and Financial Year ended December 31, 2025. The Board will also consider recommending the Final Dividend, if any, for the same financial year. The trading window remains closed until February 27, 2026.
Scheduled Board Meeting Announced
Sanofi India Limited (the “Company”) has formally informed stock exchanges regarding an upcoming meeting of its Board of Directors. This significant meeting is scheduled to convene on Wednesday, February 25, 2026.
Key Agenda Items
The Board will deliberate on several critical financial matters pertaining to the last fiscal period. The key agenda points include:
- Consideration and approval of the Audited Financial Results and Statements for both the Quarter and the full Financial Year ended 31st December 2025.
- Consideration and recommendation of the Final Dividend, if any is proposed, for the Financial Year ended 31st December 2025.
Trading Window Closure Update
Further to a prior intimation dated 26th December 2025, the Company confirmed the continued closure of the trading window. This closure is specifically for the purpose of publishing the Audited Financial Results for the period ending 31st December 2025. The window will remain shut from Thursday, 01st January 2026 through to Friday, 27th February 2026, inclusive of both dates.
The announcement was finalized and digitally signed by Haresh Vala, Company Secretary and Compliance Officer, on February 19, 2026.
Source: BSE
